Cases

PDE5 Inhibitors (Viagra, Revatio, Cialis, Adcirca)

If you’re one of the millions of men who take Viagra® or Cialis®, or if you’re one of the many who take its twin drug, Revatio® or Adcirca®, for erectile dysfunction or a high blood pressure condition known as pulmonary arterial hypertension, then you should also be aware that these medications have been associated with an increased risk for developing skin cancer, specifically melanoma.

Although these may seem like entirely unrelated conditions, as PDE5 inhibitors sildenafil, the generic name for Viagra and Revatio, and taldalafil, the generic for Cialis or Adcirca work by blocking certain pathways that would otherwise signal a decrease in blood flow in specific areas. This same function, however, may be linked to an increase in the promotion of melanoma cells.

Motley Rice pharmaceutical drug attorney Kimberly Barone Baden represents clients injured by Viagra and/or Cialis, and was appointed to and serves on the Plaintiffs’ Executive Committee for the Multidistrict Litigation, In re Viagra (sildenafil citrate) and Cialis (Tadalafil) Products Liability Litigation. Plaintiffs allege that pharmaceutical corporation and manufacturer of Viagra, Pfizer Inc., knew of an increased risk of melanoma but failed to warn the public. This litigation also includes claims against Cialis manufacturer Eli Lilly and Company that it too failed to warn of the potential risk of melanoma.

Contact a PDE5 Inhibitor Lawyer

If you or someone you know has been diagnosed with melanoma after taking Viagra, Revatio, Cialis or Adcirca, you may contact medical attorneys Kimberly Barone Baden or Ann E. Rice Ervin by email or calling 1.800.768.4026 to discuss your potential lawsuit.

Potential PDE5 Inhibitor Side Effects

More than 23 million men have been prescribed Viagra since its initial FDA approval in 1998, and sales of Revatio, manufactured by Pfizer, Inc. (NYSE: PFE), topped $338 million in 2012. In 2014, Cialis manufacturer Lilly Bio-Medicines, claimed that more than 45 million men had taken Cialis. In 2013, the drug’s sales totaled $2.2 billion worldwide and Viagra $1.9 billion.

Researchers now believe that inhibition by sildenafil or tadalafil, both generic equivalents of a phosphodiesterase PDE5 can increase melanoma cell invasion. A 2014 study published in the Journal of the American Medical Association (JAMA), “Sildenafil Use and Increased Risk of Incident Melanoma in U.S. Men,” found that men who used sildenafil to treat erectile dysfunction had almost twice the risk for developing melanoma when compared to men who had not used sildenafil, even after controlling for confounding factors such as family history of melanoma, sun exposure behavior and UV index in the state of residence.

In June 2016, the FDA announced it would study the possible link between melanoma, including that of Viagra and Cialis.